Graves' disease (GD) and Hashimoto's thyroiditis (HT) represent the commonest forms of autoimmune thyroid disease (AITD) each presenting with distinct clinical features. Progress has been made in determining association of HLA class II DRB1, DQB1 and DQA1 loci with GD demonstrating a predisposing effect for DR3 (DRB1*03-DQB1*02-DQA1*05) and a protective effect for DR7 (DRB1*07-DQB1*02-DQA1*02). Small data sets have hindered progress in determining HLA class II associations with HT. The aim of this study was to investigate DRB1-DQB1-DQA1 in the largest UK Caucasian HT case control cohort to date comprising 640 HT patients and 621 controls. A strong association between HT and DR4 (DRB1*04-DQB1*03-DQA1*03) was detected (P ¼ 6.79 Â 10 À7 , OR ¼ 1.98 (95% CI ¼ 1.51-2.59)); however, only borderline association of DR3 was found (P ¼ 0.050). Protective effects were also detected for DR13 (DRB1*13-DQB1*06-DQA1*01) (P ¼ 0.001, OR ¼ 0.61 (95% CI ¼ 0.45-0.83)) and DR7 (P ¼ 0.013, OR ¼ 0.70 (95% CI ¼ 0.53-0.93)). Analysis of our unique cohort of subjects with well characterized AITD has demonstrated clear differences in association within the HLA class II region between HT and GD. Although HT and GD share a number of common genetic markers this study supports the suggestion that differences in HLA class II genotype may, in part, contribute to the different immunopathological processes and clinical presentation of these related diseases.
Introduction
Autoimmune thyroid disease (AITD) is one of the most common autoimmune diseases (AID) affecting around 2% of the Western population, 1 with Graves' disease (GD) and Hashimoto's thyroiditis (HT) (autoimmune hypothyroidism) representing the two extremes of the disease spectrum. HT is characterized by the presence of hypothyroidism together with positive autoantibodies directed against thyroglobulin (Tg) or thyroid peroxidase (TPO), whereas in contrast GD is typified by hyperthyroidism and autoantibodies directed against the thyroid stimulating hormone receptor (TSHR), Tg and TPO. Although GD and HT present different pathological profiles, it has been suggested that these diseases share genetic susceptibility loci. Although several genes including CTLA-4 and PTPN22 have been associated with both HT and GD, [2] [3] [4] much of the work performed in HT has been on small data sets or where subjects have been grouped together with GD.
The HLA class II gene region is one such area where susceptibility loci are less well defined. Due to the crucial role played by HLA class II molecules in peptide presentation to T cells in both the periphery and during thymic selection, components of the HLA class II region have been associated with most AIDs. 5 In GD a predisposing effect for DRB1*03-DQB1*02-DQA1*05 (DR3) and a protective effect for DRB1*07-DQB1*02-DQA1*02 (DR7) have been consistently reported. 6, 7 Many small studies have investigated association of the HLA class II region with HT (Table 1) . Several associations including DRB1*03, DRB1*04 and the DR3 and DRB1*04-DQB1*03-DQA1*03 (DR4) haplotypes have been proposed 8, 13, 18, 20 however, due to a lack of replication between studies, progress in determining HLA class II associations in HT has been much slower, leaving confusion over whether GD and HT share the same susceptibility loci within this region.
Having previously performed the most comprehensive analysis of the HLA class II region in GD in a UK Caucasian cohort, the aim of the present study was to investigate the HLA class II encoded DRB1, DQA1 and DQB1 loci for association with HT using a large UK Caucasian cohort.
Results

Genotyping results
In total 625 HT cases and 619 control subjects were successfully typed at DRB1, DQB1 and DQA1 (Table 2) . Predisposing effects for HT were detected at DRB1*03, DRB1*04, DRB1*08, DQB1*04, DQB1*0301/4, DQA1* 03011/12 and DQA1*0401 (P ¼ 0.034-1.53 Â 10
À4
, odds Denotes that no data on ethnicity was given. 
Discussion
Although progress has been made in determining the genetic predisposition to GD, less is known about the genetic predisposition to HT, in part due to the use of small data sets and the assumption of genetic homogeneity between the two diseases. This study has investigated association of the HLA class II region, long known to be associated with several AIDs, in a large UK Caucasian HT case control data set.
In contrast to the consistently reported association between the DR3 haplotype and GD, the strongest association with HT in our study was the DR4 haplotype. Some evidence for a role of DRB1*04 and DR4 in HT has been previously reported in two smaller HT studies, including Japanese 17 and Italian cohorts, 19 respectively. Studies have also detected strong association of DRB1*03 and DR3 with HT, 8, 13, 18 whereas we have only detected a borderline association (P ¼ 0.050). These discrepancies between previous studies could be due to ethnic differences or the small data set size used (o400 cases and control subjects). Studies on large well-defined data sets such as those described here are important in helping to clarify the association(s) present within the HLA class II region. Our study has also detected a number of smaller novel effects for HT, including protective roles for the DR15 haplotype, which has also Table 3 Distribution of associated classical DRB1-DQB1-DQA1 haplotypes in patients with Hashimoto's thyroiditis and control subjects been seen in type 1 diabetes (T1D), and the DR13 haplotype.
HT patients recruited into the present study were part of the UK National AITD collection. 21 They are white Caucasians and are from the same sample population as our GD patients, providing a unique opportunity to perform a comparison between the two diseases. The strong association of DR4 and only borderline association of DR3 in this study is in marked contrast to that seen in our previous HLA class II studies in GD where DR3 is the strongest association. 6, 7 The data suggest, therefore, that although GD and HT fall collectively under the more general term of AITD and even though there are a number of shared genetic determinants between the AITDs 3, 4 and the AIDs in general, 22 significant differences exist within the HLA class II region.
Although autoimmune attack against components of the thyroid gland occurs in both GD and HT, the pathogeneses of the two diseases are distinct. The pathways leading to the development of GD are well documented, with the major pathogenic trigger being the production of autoantibodies against the TSHR, leading to increased thyroid hormone production. 23 The pathological basis to HT is less defined. TSHR autoantibodies, which are a key feature of GD are not present in HT although Tg and TPO autoantibodies, which are also found in GD, are typically present. A major component of HT pathogenesis is thyrocyte destruction, which has been proposed to occur through either apoptosis or necrosis, 24 processes which are not a feature of GD. Interestingly, association of components of the DR4 haplotype is not unique to HT. They have also been associated with T1D and the shared epitope (including DRB1*0401, DRB1*0404, DRB1*0405 and DRB1*0408) associated with rheumatoid arthritis (RA). 25, 26 As cell destruction is key to HT, T1D and RA this could explain why they all share either DRB1*04 or DR4 as a susceptibility locus. Functional studies performed by Schonland et al. 27 have shown that DRB1*04 positive individuals, during the first two decades of life, exhibit premature shortening of the telomeres in both CD4 þ T cells and granulocytes. This has been proposed to lead to a possible acceleration in CD4 þ T-cell replicative senescence and hence a lower than normal cell turnover. 27 Decreases in the T-cell population and repertoire could influence the ability of the immune system to respond to antigenic stimuli, with the potential that T regulatory cells exhibiting replicative senescence may not be able to prevent autoreactive cells from expanding or that senescent T cells, which are difficult to control, could attack self components. 27, 28 DRB1*04 also presents a different repertoire of peptides than DRB1*03, suggesting that components of the DR3 haplotype could be presenting antigens specific to GD, such as those derived from the TSHR, whereas DR4 could be presenting antigen derived from cell surface components of the thyrocyte leading to the differing pathogenic pathways. Although these potential mechanisms are neither mutually exclusive nor exhaustive they could help explain the differences seen within the class II region and could provide insights into the differences in clinical presentation between GD and HT.
Although there are clear differences in the development of GD and HT, the overriding common feature is that both diseases are characterized by autoantibodies directed against cellular thyroid components. Some similarities between HT and GD HLA class II susceptibility loci were detected in this study with a protective role for DRB1*07 and the DR7 haplotype and a trend toward a predisposing role for the DRB1*08 allele and DR8 haplotype. 7 This suggests that there is a degree of crossover between these AITDs, potentially explaining why both diseases present with autoantibodies against TPO and Tg. Although HT and GD undoubtedly share several common predisposing factors [2] [3] [4] at the HLA class II region, HT at least seems to share several susceptibility loci with other AIDs whose pathogenesis involves autoimmune destruction. Interestingly, the TSHR, a major GD susceptibility locus, has also not been replicated in HT. 29, 30 This suggests that when looking for AITD susceptibility loci we need to treat GD and HT as two similar but distinct diseases rather than assume an identical genetic background to both diseases as has been the case historically.
Further work in this and other HT data sets, of equal or greater size, is now needed to confirm these associations, in particular the smaller associations detected such as those between DR3, DR13 and DR15 and HT. Once these associations have been confirmed, higher resolution typing will also be required to determine the exact subtypes that are important and how variation in the encoded molecules affects peptide presentation and T-cell binding. Due to recent reports demonstrating associations within the HLA class I region independent of known HLA class II associations including association of HLA-C with GD and multiple sclerosis 31, 32 and HLA-B with T1D, 33 investigation of the remainder of the HLA region will also be required in the future to determine the exact location(s) of etiological variants within HT and investigate whether these further help to explain the differences in HT and GD pathogenesis.
Materials and methods
Subjects
Unrelated white Caucasian patients of UK origin with no history of thyroid surgery, radioiodine therapy or GD were recruited as part of the UK AITD National collection as described previously. 21 HT was defined by the presence of biochemical hypothyroidism and positive autoantibodies to Tg or TPO, the presence of lymphocytic infiltrate in a fine-needle aspirate, or the presence of a diffuse goiter on physical examination by a thyroid specialist. 21 Ethnically and gender matched control subjects with no family history of AITD were also collected as described previously. 7 All subjects gave informed written consent and the project was approved by the local research ethics committee. In total, DNA was obtained from 640 HT patients and 621 control subjects.
Genotyping DNA was extracted from whole blood using the Nucleon BACC II kit (Tepnel Life Sciences, Manchester, UK). HLA-DRB1, DQB1 and DQA1 regions were amplified using the phototyping method of PCR as described previously. 34 DYNAL AllSet þ SSP kits were employed to resolve any ambiguous results (Invitrogen, Paisley, UK). 
